<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674893</url>
  </required_header>
  <id_info>
    <org_study_id>BRINDISI 2013</org_study_id>
    <nct_id>NCT02674893</nct_id>
  </id_info>
  <brief_title>Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes</brief_title>
  <acronym>GLP1 et Goût</acronym>
  <official_title>Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      This is an open-label comparative study in three parallel groups. It is expected that 90&#xD;
      patients and/or healthy volunteers will participate in this biomedical research.&#xD;
&#xD;
      Distribution in groups&#xD;
&#xD;
        -  30 patients with type 2 diabetes and an indication for treatment with a GLP1 analogue&#xD;
           (group 1)&#xD;
&#xD;
        -  30 patients with type 2 diabetes (control diabetic subjects) not treated with Incretins&#xD;
           (group 2)&#xD;
&#xD;
        -  30 healthy subjects (non-diabetics) (group 3)&#xD;
&#xD;
      This study will investigate modifications in eating behaviour induced by Liraglutide in&#xD;
      patients who start treatment with Victoza® and certain aspects, such as liking (hedonic&#xD;
      characteristic of a food), wanting (desire to eat a given food) and salivation in response to&#xD;
      the presentation of a food by taking measurements at D0 (before initiation of the treatment&#xD;
      with Liraglutide in the group concerned) then at 15 days (except for the controls), 3 months&#xD;
      and 9 months (only for controls).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Exploratory protocol, convincing results, robust analysis&#xD;
  </why_stopped>
  <start_date type="Actual">February 4, 2014</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
  </study_design_info>
  <primary_outcome>
    <measure>Modifications in wanting</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modifications in gustatory performance</measure>
    <time_frame>Until 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifications in liking</measure>
    <time_frame>Until 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifications in salivation following the presentation of foods</measure>
    <time_frame>Until 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifications in optimal preferences for sweet and fatty tastes</measure>
    <time_frame>Until 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric modifications</measure>
    <time_frame>Until 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>type 2 diabetics treated with GLP1 analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetics not treated with incretins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>type 2 diabetics treated with GLP1 analogue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation alone</intervention_name>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Type 2 diabetics not treated with incretins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE&#xD;
&#xD;
          -  persons who have provided written informed consent&#xD;
&#xD;
          -  aged &gt; 18 years&#xD;
&#xD;
          -  type 2 diabetes with HbA1C &gt; 7%&#xD;
&#xD;
          -  overweight (BMI &gt; 27)&#xD;
&#xD;
          -  normal renal function (creatinine clearance &gt; 50ml/min)&#xD;
&#xD;
          -  patients to be treated with Liraglutide (patients with type 2 diabetes with HbA1C &gt;&#xD;
             7.5% and overweight or obesity, whose current treatment is insufficient to control the&#xD;
             diabetes).&#xD;
&#xD;
        CONTROL DIABETIC PATIENTS&#xD;
&#xD;
          -  persons who have provided written informed consent&#xD;
&#xD;
          -  aged &gt; 18 years&#xD;
&#xD;
          -  type 2 diabetes with HbA1C &gt; 7%&#xD;
&#xD;
          -  overweight (BMI &gt; 27)&#xD;
&#xD;
          -  patients for whom treatment with Liraglutide is not indicated&#xD;
&#xD;
          -  normal renal function (creatinine clearance &gt; 50ml/min)&#xD;
&#xD;
        HEALTHY SUBJECTS&#xD;
&#xD;
          -  persons who have provided written informed consent&#xD;
&#xD;
          -  aged &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  decompensated congestive heart failure&#xD;
&#xD;
          -  acute or chronic infection, progressive cancer, liver cirrhosis&#xD;
&#xD;
          -  ongoing treatment with antibiotics&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  chronic alcohol abuse (&gt;4 glasses a day)&#xD;
&#xD;
          -  aversion to the products to be eaten or smelled&#xD;
&#xD;
          -  poor understanding of the cognitive tasks requested&#xD;
&#xD;
          -  treatment interfering with olfactogustatory performance, such as psychotropic,&#xD;
             anti-emetic and anti-ulcer drugs&#xD;
&#xD;
          -  persons without national health insurance cover&#xD;
&#xD;
          -  persons under guardianship&#xD;
&#xD;
          -  hypersensitivity to Liraglutide&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  history of acute or chronic pancreatitis&#xD;
&#xD;
          -  calcitonin level at selection ≥ 50 ng/L&#xD;
&#xD;
          -  liver disease, defined by a level of alanine aminotransferase (ALAT) ≥ 2.5 times the&#xD;
             upper limit of normal (ULN) for reference values&#xD;
&#xD;
        CONTROL DIABETIC PATIENTS&#xD;
&#xD;
          -  type 1 diabetes,&#xD;
&#xD;
          -  decompensated congestive heart failure,&#xD;
&#xD;
          -  acute or chronic infection, progressive cancer, liver cirrhosis,&#xD;
&#xD;
          -  ongoing treatment with antibiotics,&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  chronic alcohol abuse (&gt; 4 glasses a day),&#xD;
&#xD;
          -  aversion to the products to be eaten or smelled,&#xD;
&#xD;
          -  poor understanding of the cognitive tasks requested,&#xD;
&#xD;
          -  treatment interfering with olfactogustatory performance, such as psychotropic,&#xD;
             anti-emetic and anti-ulcer drugs.&#xD;
&#xD;
          -  persons without national health insurance cover&#xD;
&#xD;
          -  persons under guardianship&#xD;
&#xD;
        HEALTHY SUBJECTS&#xD;
&#xD;
          -  diabetes (type I and II)&#xD;
&#xD;
          -  sensory disorders&#xD;
&#xD;
          -  decompensated congestive heart failure,&#xD;
&#xD;
          -  acute or chronic infection, progressive cancer, liver cirrhosis,&#xD;
&#xD;
          -  ongoing treatment with antibiotics,&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  chronic alcohol abuse (&gt; 4 glasses a day),&#xD;
&#xD;
          -  aversion to the products to be eaten or smelled,&#xD;
&#xD;
          -  poor understanding of the cognitive tasks requested,&#xD;
&#xD;
          -  treatment interfering with olfactogustatory performance (psychotropic, anti-emetic,&#xD;
             anti-ulcer drugs)&#xD;
&#xD;
          -  persons without national health insurance cover&#xD;
&#xD;
          -  persons under guardianship&#xD;
&#xD;
          -  contra-indications to MRI, notably, but not limited to: pace maker, implantable&#xD;
             cardiac defibrillators, neurostimulators, cochlear implants, certain implanted&#xD;
             automated injection systems (insulin pumps), vascular intracerebral ferromagnetic&#xD;
             clips, certain systems to regulate intravascular temperature, myopia requiring the&#xD;
             patients to wear spectacle, history of stroke or transient ischemic attack (TIA),&#xD;
             metallic foreign body, in particular intraocular or situated near high-risk zones&#xD;
             (nervous system, vascular system), claustrophobia….&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMI&gt;27</keyword>
  <keyword>Treatment with Liraglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

